Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals

Objective—Blood-borne biomarkers reflecting atherosclerotic plaque burden have great potential to improve clinical management of atherosclerotic coronary artery disease and acute coronary syndrome (ACS). Approach and Results—Using data integration from gene expression profiling of coronary thrombi versus peripheral blood mononuclear cells and proteomic analysis of atherosclerotic plaque–derived secretomes versus healthy tissue secretomes, we identified fatty acid–binding protein 4 (FABP4) as a biomarker candidate for coronary artery disease. Its diagnostic and prognostic performance was validated in 3 different clinical settings: (1) in a cross-sectional cohort of patients with stable coronary artery disease, ACS, and healthy individuals (n=820), (2) in a nested case–control cohort of patients with ACS with 30-day follow-up (n=200), and (3) in a population-based nested case–control cohort of asymptomatic individuals with 5-year follow-up (n=414). Circulating FABP4 was marginally higher in patients with ST-segment–elevation myocardial infarction (24.9 ng/mL) compared with controls (23.4 ng/mL; P=0.01). However, elevated FABP4 was associated with adverse secondary cerebrovascular or cardiovascular events during 30-day follow-up after index ACS, independent of age, sex, renal function, and body mass index (odds ratio, 1.7; 95% confidence interval, 1.1–2.5; P=0.02). Circulating FABP4 predicted adverse events with similar prognostic performance as the GRACE in-hospital risk score or N-terminal pro–brain natriuretic peptide. Finally, no significant difference between baseline FABP4 was found in asymptomatic individuals with or without coronary events during 5-year follow-up. Conclusions—Circulating FABP4 may prove useful as a prognostic biomarker in risk stratification of patients with ACS.

[1]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[2]  H. Katus,et al.  Cardiac troponin level elevations not related to acute coronary syndromes , 2013, Nature Reviews Cardiology.

[3]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[4]  S. Kusachi,et al.  Association of increased plasma adipocyte fatty acid-binding protein with coronary artery disease in non-elderly men , 2011, Cardiovascular diabetology.

[5]  J. Girona,et al.  Fatty acid binding protein 4 is increased in metabolic syndrome and with thiazolidinedione treatment in diabetic patients. , 2007, Atherosclerosis.

[6]  Muredach P. Reilly,et al.  Relation of plasma fatty acid binding proteins 4 and 5 with the metabolic syndrome, inflammation and coronary calcium in patients with type-2 diabetes mellitus. , 2010, The American journal of cardiology.

[7]  Dong Zhao,et al.  Predictive value for the Chinese population of the Framingham CHD risk assessment tool compared with the Chinese Multi-Provincial Cohort Study. , 2004, JAMA.

[8]  A. Xu,et al.  Serum Adipocyte Fatty Acid-Binding Protein Levels Were Independently Associated With Carotid Atherosclerosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[9]  L. Razzouk,et al.  Novel Biomarkers for Risk Stratification and Identification of Life-threatening Cardiovascular Disease: Troponin and Beyond , 2012, Current cardiology reviews.

[10]  A. von Eckardstein,et al.  Antibody Phage Display Assisted Identification of Junction Plakoglobin as a Potential Biomarker for Atherosclerosis , 2012, PloS one.

[11]  G. Lamas,et al.  ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients wi , 2004, Journal of the American College of Cardiology.

[12]  V. Salomaa,et al.  Low-Expression Variant of Fatty Acid–Binding Protein 4 Favors Reduced Manifestations of Atherosclerotic Disease and Increased Plaque Stability , 2014, Circulation. Cardiovascular genetics.

[13]  S. Kusachi,et al.  Serum adipocyte fatty acid-binding protein is independently associated with coronary atherosclerotic burden measured by intravascular ultrasound. , 2010, Atherosclerosis.

[14]  P. Collinson.  The role of cardiac biomarkers in cardiovascular disease risk assessment , 2014, Current opinion in cardiology.

[15]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[16]  D. Birchall,et al.  Increased expression of fatty acid binding protein 4 and leptin in resident macrophages characterises atherosclerotic plaque rupture , 2013, Atherosclerosis.

[17]  M. Fasshauer,et al.  Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein , 2011 .

[18]  M. Fasshauer,et al.  Metabolic and genetic predictors of circulating adipocyte fatty acid-binding protein , 2011, International Journal of Obesity.

[19]  M. Fasshauer,et al.  Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease? , 2012, Diabetologia.

[20]  Jennifer G. Robinson,et al.  2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines , 2014, Circulation.

[21]  Jeffrey B. Boord,et al.  Lack of macrophage fatty-acid–binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis , 2001, Nature Medicine.

[22]  F. Eberli,et al.  Cellular actors, Toll-like receptors, and local cytokine profile in acute coronary syndromes. , 2010, European heart journal.

[23]  A. Jaffe,et al.  2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[24]  F. Moll,et al.  Adipocyte fatty acid binding protein in atherosclerotic plaques is associated with local vulnerability and is predictive for the occurrence of adverse cardiovascular events. , 2011, European heart journal.

[25]  S. Hoerstrup,et al.  Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes , 2014, European heart journal.

[26]  Vincent Mooser,et al.  The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome , 2008, BMC cardiovascular disorders.

[27]  H. Brenner,et al.  Circulating Adipocyte Fatty Acid-Binding Protein Levels and Cardiovascular Morbidity and Mortality in Patients With Coronary Heart Disease: A 10-year Prospective Study , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[28]  Á. Avezum,et al.  Predictors of hospital mortality in the global registry of acute coronary events. , 2003, Archives of internal medicine.

[29]  A. Stenzl,et al.  Monitoring high-risk bladder cancer , 2012, Current opinion in urology.

[30]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. , 2013, Journal of the American College of Cardiology.

[31]  R. Erbel,et al.  Comparative study of clinical characteristics between Chinese Han and German Caucasian patients with coronary heart disease , 2009, Clinical Research in Cardiology.

[32]  Jennifer G. Robinson,et al.  ACCF/AHA TASK FORCE MEMBERS , 2013 .

[33]  Bernadette A. Thomas,et al.  Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 , 2015, The Lancet.

[34]  W. Qiu,et al.  Risk scores in acute coronary syndrome and percutaneous coronary intervention: a review. , 2013, American heart journal.

[35]  K. Kanmatsuse,et al.  [Pathogenesis of acute coronary syndromes]. , 1998, Nihon rinsho. Japanese journal of clinical medicine.

[36]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.

[37]  B. Cheung,et al.  Elevated Circulating Adipocyte‐Fatty Acid Binding Protein Levels Predict Incident Cardiovascular Events in a Community‐Based Cohort: A 12‐Year Prospective Study , 2013, Journal of the American Heart Association.